Maxim Group Cuts Theriva Biologics (NYSEAMERICAN:TOVX) Price Target to $6.00

Theriva Biologics (NYSEAMERICAN:TOVX) had its target price trimmed by Maxim Group from $25.00 to $6.00 in a research note released on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Theriva Biologics Trading Up 0.7 %

TOVX opened at $1.36 on Wednesday. The company has a market capitalization of $3.09 million, a P/E ratio of -0.04 and a beta of 1.34. Theriva Biologics has a 12-month low of $1.24 and a 12-month high of $17.11.

Theriva Biologics (NYSEAMERICAN:TOVX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($6.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.25) by ($0.56).

Institutional Investors Weigh In On Theriva Biologics

A hedge fund recently bought a new stake in Theriva Biologics stock. Anson Funds Management LP acquired a new position in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned approximately 6.13% of Theriva Biologics at the end of the most recent reporting period. Institutional investors and hedge funds own 6.17% of the company’s stock.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.